Lane 03 — Mental health.

Consult room 02, 4:14 pm — winter slant light against the desk.

Minute 03 — Why a primary-care practice runs this lane

The United States is roughly 30,000 psychiatrists short of demand, and the wait for a new psychiatric appointment in the Twin Ports region is currently sitting around four months. The math on outpatient psychiatry has been broken for a decade and is not improving¹. Primary care has, by attrition, become the de-facto front door to mental-health treatment in the United States: a 2010 analysis² found that primary-care clinicians prescribe roughly 60% of all antidepressants and a comparable share of stimulants. We accept the consequence: this lane is a real part of what we do, not a secondary one, and we staff it with a psychiatric mental-health nurse practitioner (Satya Nair, PMHNP-BC) rather than treating it as something the family physician squeezes between blood-pressure visits.

Week 02 — Depression, with PHQ-9 as a clock

We screen with the PHQ-9 at every annual visit, in line with the USPSTF B recommendation for depression screening in the general adult population. A score of 10 or higher prompts a structured conversation, not an automatic prescription. Where a member and clinician decide together that pharmacotherapy is indicated, we start most patients on sertraline 50 mg (twenty-five-cent tablets at our cost, $3.85 for ninety) and follow up at week two and week six. We do not start escitalopram first by default; the head-to-head MANGA meta-analysis³ showed only modest separation among first-line SSRIs, and our preference is mostly logistical (sertraline tolerates abrupt cessation better, weighs less on the QT, plays better with future pregnancies).

We do not stop a working SSRI before twelve months of remission. We do taper, slowly, when stopping; we believe the Horowitz & Taylor 2019 hyperbolic-tapering paper⁴. Most members in our panel taper over six to eighteen weeks. Some take longer. We are not in a hurry.

Week 04 — Anxiety, and the benzodiazepine question

For generalized anxiety disorder we follow a similar SSRI-first approach with the same drugs (sertraline, escitalopram) and add cognitive-behavioral therapy as the parallel intervention; for panic disorder we add the same therapy with a different topology and titrate more slowly. We do not, as a default, prescribe benzodiazepines for chronic anxiety. The members who arrive on a long-standing benzodiazepine often want help getting off it, and the literature on slow tapering⁵ is reassuring: an Ashton-protocol-style taper, a switch to a long-acting agent (clonazepam or chlordiazepoxide) where appropriate, and a multi-month wind-down. We do not white-knuckle people through cessation. We also do not prescribe a benzodiazepine for the first time in this practice without a documented reason that does not include "I have always taken one."

Week 06 — ADHD continuation

We accept ADHD continuation prescriptions for adult members already established on stimulant therapy when they enrolled, where the diagnosis was made by a qualified clinician, where there is a current treatment plan that we can read, and where the member is willing to follow our requirements: a registered Minnesota PMP query at every refill, a single pharmacy on file, a paper-only Schedule II prescription per state law, and a yearly visit at minimum. We do not initiate adult ADHD diagnoses in this practice; the workup that would deserve the diagnostic label is not something a thirty-minute primary-care visit can responsibly produce. For new diagnostic workups we refer to University of Minnesota Medical School's adult ADHD clinic in the Twin Cities or to our local consulting psychiatrist Dr. Maya Cassirer, MD.

Buprenorphine, without theater

As of the 2022 Mainstreaming Addiction Treatment Act (the "MAT Act"), the X-waiver is gone. Any DEA-registered prescriber can write buprenorphine for opioid use disorder. We do; for nine of our active members at present. The framework we use is the SAMHSA TIP-63⁶, with the home-induction modification described by the CDC's 2023 substance-use clinical guidance.

We do not require a urine drug screen as a condition of induction. We do not discharge for a return-to-use; a return-to-use means we missed something in the last visit and we want the next visit. We do not require attendance at a 12-step program; we are not opposed to a member attending one if they choose, and we will note it on the chart. The literature on the relative weight of medication versus counseling in OUD recovery is unambiguous on which one is doing most of the work⁷, and so are we. Case log 004 is a working buprenorphine induction we walk through in detail.

Tools — controlled-substance prescribing

All Schedule II prescriptions in Minnesota are paper-only, single-pharmacy, dated to the day of issue, and PMP-checked at each refill. We use a triplicate Rx pad supplied by the state board; a copy is filed in the chart and a duplicate is sent to the dispensing pharmacy by fax (yes, fax — the Minnesota Board of Pharmacy still requires it for Schedule II). We do not text photos of prescriptions. We do not "phone in" Schedule II refills. We will lose your prescription exactly once before we ask you to stop losing prescriptions, and that conversation is not a punishment; it is a request.

Tools — the therapy referral list

We do not provide psychotherapy. We do refer to four therapists in town with whom we have working relationships: Dr. Idris Wahlquist, PhD (CBT, anxiety, sleep) on Lake Avenue; Maren Aaberg, LICSW (DBT-informed, trauma-focused, accepts most insurance) at Lake Superior Community Health Center; Solveig Ek, PsyD (perimenopause, life transitions, grief) in private practice on East Hillside; and Dr. Hadi Ghorbani, PhD (couples and family) on Park Point. Their sliding scales, current waits, and insurance panels are on file at the front desk. Members with a strong preference for any of those panels can ask Nair at the next visit; the warm handoff is a phone call.

Cross-references: this lane meets 06 · Perimenopause at the sleep-and-mood interface; it meets 01 · Cardiometabolic at the antidepressant-weight-and-metabolic conversation; and it meets 08 · End-of-life at the existential-distress edges of palliative care. The transcript "Buprenorphine without theater" walks through what that phrase actually means.